CA2793900A1 - Oxazole derivatives useful as modulators of faah - Google Patents
Oxazole derivatives useful as modulators of faah Download PDFInfo
- Publication number
- CA2793900A1 CA2793900A1 CA2793900A CA2793900A CA2793900A1 CA 2793900 A1 CA2793900 A1 CA 2793900A1 CA 2793900 A CA2793900 A CA 2793900A CA 2793900 A CA2793900 A CA 2793900A CA 2793900 A1 CA2793900 A1 CA 2793900A1
- Authority
- CA
- Canada
- Prior art keywords
- halo
- 4alkyl
- mono
- optionally substituted
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/46—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32199210P | 2010-04-08 | 2010-04-08 | |
| US61/321,992 | 2010-04-08 | ||
| PCT/US2011/031040 WO2011126960A1 (en) | 2010-04-08 | 2011-04-04 | Oxazole derivatives useful as modulators of faah |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2793900A1 true CA2793900A1 (en) | 2011-10-13 |
Family
ID=44763231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2793900A Abandoned CA2793900A1 (en) | 2010-04-08 | 2011-04-04 | Oxazole derivatives useful as modulators of faah |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9193697B2 (https=) |
| EP (1) | EP2555772B1 (https=) |
| JP (1) | JP2013523814A (https=) |
| CN (1) | CN102917704A (https=) |
| AU (1) | AU2011238487B2 (https=) |
| BR (1) | BR112012023974A2 (https=) |
| CA (1) | CA2793900A1 (https=) |
| WO (1) | WO2011126960A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2321288B1 (en) * | 2008-08-04 | 2014-03-19 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as inhibitors of faah |
| US9006433B2 (en) | 2010-04-21 | 2015-04-14 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| BR112019016241A2 (pt) | 2017-02-08 | 2020-04-07 | Bayer Cropscience Ag | derivados de triazol e seu uso como fungicidas |
| CA3052519A1 (en) | 2017-02-08 | 2018-08-16 | Andreas Gortz | Triazolethione derivatives |
| US20200045967A1 (en) | 2017-02-08 | 2020-02-13 | Bayer Cropscience Aktiengesellschaft | Novel triazole derivatives |
| KR20190115449A (ko) | 2017-02-10 | 2019-10-11 | 바이엘 악티엔게젤샤프트 | 1-(페녹시-피리디닐)-2-(1,2,4-트리아졸-1-일)-에탄올 유도체를 포함하는 유해 미생물을 방제하기 위한 조성물 |
| IL271149B2 (en) * | 2017-06-14 | 2024-05-01 | Trevena Inc | Compounds for modulating s1p1 activity and methods of using the same |
| WO2020020816A1 (en) | 2018-07-26 | 2020-01-30 | Bayer Aktiengesellschaft | Novel triazole derivatives |
| CN110804048A (zh) * | 2019-11-08 | 2020-02-18 | 暨南大学 | 恶唑酮类化合物及其应用、faah的正电子药物 |
| EP4061352A4 (en) | 2019-11-19 | 2024-02-28 | Trevena, Inc. | COMPOUNDS AND METHODS FOR PRODUCING S1P1-MODULATING COMPOUNDS |
| WO2025048475A1 (ko) * | 2023-08-29 | 2025-03-06 | 고려대학교 세종산학협력단 | 옥사졸 유사체를 유효성분으로 포함하는 항노화 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009538358A (ja) * | 2006-05-26 | 2009-11-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター |
| FR2921063B1 (fr) | 2007-09-13 | 2009-12-11 | Sod Conseils Rech Applic | Ligands des recepteurs cannabinoides |
| CA2727245A1 (en) | 2008-06-11 | 2009-12-17 | Merck Sharp & Dohme Corp. | Imidazole derivatives useful as inhibitors of faah |
| EP2321288B1 (en) * | 2008-08-04 | 2014-03-19 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as inhibitors of faah |
| BR112012018913A2 (pt) * | 2010-01-28 | 2017-06-20 | Merck Sharp & Dohme | "composição farmacêutica, e, uso da composição" |
-
2011
- 2011-04-04 JP JP2013503806A patent/JP2013523814A/ja active Pending
- 2011-04-04 EP EP11766539.8A patent/EP2555772B1/en active Active
- 2011-04-04 WO PCT/US2011/031040 patent/WO2011126960A1/en not_active Ceased
- 2011-04-04 BR BR112012023974A patent/BR112012023974A2/pt not_active IP Right Cessation
- 2011-04-04 CA CA2793900A patent/CA2793900A1/en not_active Abandoned
- 2011-04-04 US US13/635,303 patent/US9193697B2/en active Active
- 2011-04-04 CN CN2011800173842A patent/CN102917704A/zh active Pending
- 2011-04-04 AU AU2011238487A patent/AU2011238487B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2555772B1 (en) | 2017-01-11 |
| AU2011238487A1 (en) | 2012-09-13 |
| CN102917704A (zh) | 2013-02-06 |
| JP2013523814A (ja) | 2013-06-17 |
| AU2011238487B2 (en) | 2015-10-01 |
| US20130018048A1 (en) | 2013-01-17 |
| US9193697B2 (en) | 2015-11-24 |
| WO2011126960A1 (en) | 2011-10-13 |
| EP2555772A1 (en) | 2013-02-13 |
| BR112012023974A2 (pt) | 2017-09-26 |
| EP2555772A4 (en) | 2013-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011238487B2 (en) | Oxazole derivatives useful as modulators of FAAH | |
| EP2321288B1 (en) | Oxazole derivatives useful as inhibitors of faah | |
| AU2011242961B2 (en) | Oxazole derivatives useful as modulators of FAAH | |
| US8455528B2 (en) | Imidazole derivatives useful as inhibitors of FAAH | |
| US20110021531A1 (en) | Oxazole derivatives useful as inhibitors of faah | |
| EP2566481A1 (en) | Aza-indole derivatives useful as modulators of faah | |
| AU2010221650B2 (en) | Imidazole derivatives useful as modulators of FAAH and as FAAH imaging agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160404 |
|
| FZDE | Dead |
Effective date: 20180404 |